REVIEWERS COMMENTS. Although it is not commercially available in the United States, SLIT for pollen allergy has gained widespread acceptance in Europe, and evidence supporting its safety and efficacy is accumulating. The promise of SLIT is that it might provide a safer and more-convenient alternative to subcutaneous immunotherapy while maintaining efficacy. Much of the literature supporting its...

Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease-modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to th...

A basic mathematical model of the immune response when cancer cells are recognized is proposed. The model consists of six ordinary differential equations. It is extended by taking into account two types of immunotherapy: active immunotherapy and adoptive immunotherapy. An analysis of the corresponding models is made to answer the question which of the presented methods of immunotherapy is bette...

Background: The importance of immunotherapy in cancer treatment has been increased owing to its non-toxicity and application to personalized medicine. However, precise estimation indices of immunotherapy have yet to be established. To determine effective evaluation indices of immunotherapy for cancer treatment, we analyzed the CD4/CD8 ratio under various conditions in clinical patients with adv...

BACKGROUND Although many patients with allergic rhinitis have symptoms due to sensitization to more than one kind of allergens, and mixed allergen extracts are widely used for immunotherapy, there are few published trials. OBJECTIVE Our study aimed to evaluate the effect of multiple-allergen immunotherapy on improving the symptoms and quality of life of allergic rhinitis patients. METHODS W...

given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. immunotherapy, an approach to harness normal immune cells against cancers not only today’s breakthrough but in fact the future of oncology therapeutics. taking into consideration the recent approvals for new lines of therapy inclu...

background: recurrent miscarriage (rm) affects 2-5% of pregnant women. paternal lymphocyte immunotherapy is a common treatment for rm patients but the outcome has not been consistent. therefore, combined therapy with other immunosuppressive drugs such as 1 a, 25-dihydroxy-vitamin-d3 (vitamin d3) may improve the outcome. objectives: to investigate the effect of vitamin d3 on the balance of two e...

Tumor-associated macrophages M2 (TAM2), which are highly prevalent infiltrating immune cells in the stroma of pancreatic cancer (PC), have been found to induce an immunosuppressive tumor microenvironment, thus enhancing initiation and progression. However, therapy response prognostic significance regulatory genes associated with TAM2 PC currently unknown. Based on TCGA transcriptomic data singl...

Adoptive T-cell transfer is among the most promising immunotherapies against cancer. To continue increasing the potential of this therapy, our studies focus on the inhibition of tumor recurrence. Recently, we have demonstrated several ways in which combination therapies involving multiple T-cell populations and immunostimulatory chemotherapy can enhance long-term survival.